Home - Products - Inhibitors & Agonists - Cell Cycle/DNA Damage - Details

FX-909（FX 909；FX909）CAS No.: 2924573-90-8

Chemical Structure : FX-909
CAS No.: 2924573-90-8

Send Inquiry

Description

Chemical Structure : FX-909

CAS No.: 2924573-90-8

FX-909 （FX 909；FX909）

Catalog No.: URK-V2454 Only Used For Lab.

FX-909 is a novel ,potent selective inhibits kinase 7 (CDK7).

Biological Activity

FX-909 is a novel, potent, selective inhibits kinase 7 (CDK7).
CDK7 is a key player in the regulation of transcription, the process by which genetic information is converted into proteins. By inhibiting CDK7, FX-909 disrupts the progression of the cell cycle, which is often dysregulated in cancer cells. This leads to a decrease in the proliferation of cancer cells and ultimately tumor growth.
Preclinical studies have shown that FX-909 has potent antitumor activity in various cancer cell lines, including breast, lung, and prostate cancers. In addition, it has demonstrated favorable pharmacokinetic properties and good tolerability in animal models.

Physicochemical Properties

M.Wt	360.33
Formula	C₁₇H₁₀F₂N₂O₃S
CAS No.	2924573-90-8
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell. 2014;159(5):1126-39.

2. Cao Q, Lu X, Feng Y, Li K, Wang L, Lv Y. CDK7 inhibition is a promising therapeutic approach in solid tumors. BMC Cancer. 2019;19(1):758.

3. Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616-20.